Clinical Trial Update: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating acalabrutinib with anti-CD20 therapy and venetoclax in relapsed/refractory or untreated chronic lymphocytic leukemia, small lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: COMPLETED